SCHEMBL22856442

SCHEMBL22856442

Cn1c(=O)n(C2CCC(O)NC2=O)c2ccc(Br)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 4/20 0.43
▸ CRBN Q96SW2 4/20 0.43
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ BRPF1 P55201 2/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ BRD1 O95696 1/20 0.33
▸ BRPF3 Q9ULD4 1/20 0.33
▸ HPD P32754 3/20 0.33
▸ MCL1 Q07820 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27284350 0.88 DDB1 (0.45) DDB1CRBNMEN1KMT2AATM
SCHEMBL20845772 0.85 DDB1 (0.43) DDB1CRBNDRD2SLC6A4KDM4E
SCHEMBL23806387 0.83 DDB1 (0.42) DDB1CRBNDRD2SLC6A4BRPF1
SCHEMBL25580189 0.83 DDB1 (0.42) DDB1CRBNDRD2SLC6A4BRPF1
SCHEMBL20840208 0.79 CRBN (0.70) DDB1CRBNALDH1A1TDP1OPRM1
SCHEMBL31748074 0.78 DDB1 (0.43) DDB1CRBNMEN1KMT2AATM
SCHEMBL23842396 0.77 DDB1 (0.38) DDB1CRBNDRD2SLC6A4BRPF1
SCHEMBL24779909 0.77 DDB1 (0.43) DDB1CRBN
SCHEMBL24481217 0.77 DDB1 (0.38) DDB1CRBNBRPF1BRD1HPD
SCHEMBL31730119 0.77 CRBN (0.60) DDB1CRBNDRD2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2021188948-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885MEN1 4055/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885MEN1 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback